Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Celularity (Nasdaq: CELU), a regenerative medicine company, has filed its Q1 and Q2 2025 Form 10-Q reports and regained compliance with Nasdaq Listing Rule 5250(c)(1). The company has made significant progress in addressing financial challenges, including the retirement of $32.0 million in senior secured debt plus $9.6 million in unpaid interest.
Under CEO Robert J. Hariri's leadership, Celularity has implemented strategic changes including an internal restructuring with dedicated operating subsidiaries for each business unit. The company faced working capital pressures in H1 2025 due to wound care product reimbursement uncertainty and delayed cash collections. Management now believes Celularity is positioned to access traditional working capital facilities to support wound care sales growth and advance its three late-stage 510(k) pipeline products.
Celularity (Nasdaq: CELU), azienda di medicina rigenerativa, ha depositato i rapporti Form 10-Q relativi al primo e al secondo trimestre 2025, ripristinando la conformità alla Regola di quotazione Nasdaq 5250(c)(1). L'azienda ha compiuto progressi rilevanti nella gestione delle criticità finanziarie, incluso il rimborso di 32,0 milioni di dollari di debito garantito senior più 9,6 milioni di dollari di interessi non pagati.
Sotto la guida dell'amministratore delegato Robert J. Hariri, Celularity ha avviato cambiamenti strategici, tra cui una riorganizzazione interna con sussidiarie operative dedicate a ciascuna unità di business. Nel primo semestre 2025 l'azienda ha affrontato tensioni di capitale circolante a causa dell'incertezza sui rimborsi dei prodotti per la cura delle ferite e dei ritardi nelle riscossioni. Ora la direzione ritiene che Celularity sia nelle condizioni di accedere a linee di capitale circolante tradizionali per sostenere la crescita delle vendite nel wound care e portare avanti i suoi tre prodotti in fase avanzata della pipeline 510(k).
Celularity (Nasdaq: CELU), una compañía de medicina regenerativa, presentó sus informes Form 10-Q del primer y segundo trimestre de 2025 y recuperó la conformidad con la Norma de cotización Nasdaq 5250(c)(1). La empresa ha avanzado de manera significativa en la resolución de sus dificultades financieras, incluyendo la cancelación de 32,0 millones de dólares de deuda garantizada sénior más 9,6 millones de dólares en intereses no pagados.
Bajo la dirección del CEO Robert J. Hariri, Celularity implementó cambios estratégicos, entre ellos una reestructuración interna con filiales operativas dedicadas a cada unidad de negocio. En el primer semestre de 2025 la compañía afrontó presiones de capital de trabajo por la incertidumbre en el reembolso de productos para el cuidado de heridas y retrasos en la cobranza. La dirección considera ahora que Celularity está en posición de acceder a líneas tradicionales de capital de trabajo para impulsar el crecimiento de las ventas en wound care y avanzar sus tres productos en fase avanzada de la pipeline 510(k).
Celularity (나스닥: CELU)는 재생 의학 회사로서 2025년 1분기 및 2분기 Form 10-Q 보고서를 제출하여 나스닥 상장 규정 5250(c)(1) 준수를 회복했습니다. 회사는 재무적 문제 해결에 있어 중요한 진전을 이루었으며, 3,200만 달러의 선순위 담보부 채무와 960만 달러의 미지급 이자를 상환한 바 있습니다.
로버트 J. 하리리(Robert J. Hariri) CEO의 리더십 아래 Celularity는 각 사업부에 전담 운영 자회사를 두는 내부 구조조정 등 전략적 변화를 단행했습니다. 2025년 상반기에는 상처 치료 제품의 보험급여 불확실성과 현금 회수 지연으로 운전자본 압박을 겪었으나, 경영진은 이제 Celularity가 전통적인 운전자본 시설에 접근해 wound care 매출 성장을 지원하고 510(k) 파이프라인의 3개 후기 단계 제품을 진전시킬 수 있는 위치에 있다고 보고 있습니다.
Celularity (Nasdaq: CELU), société de médecine régénérative, a déposé ses rapports Form 10-Q pour le premier et le deuxième trimestre 2025 et a retrouvé la conformité à la règle de cotation Nasdaq 5250(c)(1). L'entreprise a réalisé des progrès significatifs pour résoudre ses difficultés financières, notamment le rachat de 32,0 millions de dollars de dette senior garantie plus 9,6 millions de dollars d'intérêts impayés.
Sous la direction du PDG Robert J. Hariri, Celularity a mis en œuvre des changements stratégiques, y compris une restructuration interne avec des filiales opérationnelles dédiées à chaque unité commerciale. Au premier semestre 2025, la société a subi des tensions de fonds de roulement en raison de l'incertitude concernant le remboursement des produits de soins des plaies et des retards de recouvrement. La direction estime désormais que Celularity est en position d'accéder à des facilités de financement de fonds de roulement traditionnelles pour soutenir la croissance des ventes en wound care et faire progresser ses trois produits en phase avancée de la pipeline 510(k).
Celularity (Nasdaq: CELU), ein Unternehmen für regenerative Medizin, hat seine Form 10-Q-Berichte für das erste und zweite Quartal 2025 eingereicht und damit die Einhaltung der Nasdaq-Listenregel 5250(c)(1) wiederhergestellt. Das Unternehmen hat bedeutende Fortschritte bei der Bewältigung finanzieller Herausforderungen erzielt, einschließlich der Tilgung von 32,0 Millionen US-Dollar an vorrangig besicherten Schulden zuzüglich 9,6 Millionen US-Dollar an nicht gezahlten Zinsen.
Unter der Leitung von CEO Robert J. Hariri hat Celularity strategische Maßnahmen umgesetzt, darunter eine interne Umstrukturierung mit eigenen operativen Tochtergesellschaften für jede Geschäftseinheit. Im ersten Halbjahr 2025 stand das Unternehmen unter Druck des Umlaufkapitals aufgrund von Unsicherheiten bei der Erstattung von Wundversorgungsprodukten und verzögerten Zahlungseingängen. Das Management ist nun der Ansicht, dass Celularity in der Lage ist, traditionelle kurzfristige Finanzierungslinien zu nutzen, um das Umsatzwachstum im Wundbereich zu unterstützen und seine drei späten 510(k)-Pipeline-Produkte voranzubringen.
- Retirement of $32.0 million senior secured debt and $9.6 million in unpaid interest
- Regained Nasdaq listing compliance
- Restructuring completed with dedicated operating subsidiaries for each business unit
- Three late-stage 510(k) pipeline products in development
- Company now positioned to access traditional working capital facilities
- Faced significant working capital pressures in H1 2025
- Experienced delays in cash collections from wound care product sales
- Encountered uncertainty around wound care product reimbursement policy
Insights
Celularity regains Nasdaq compliance and eliminates $41.6M debt, significantly strengthening financial position despite earlier cash flow challenges.
Celularity has successfully addressed two critical issues that were threatening the company's stability. First, by filing its delayed Q1 and Q2 2025 reports, the company has regained compliance with Nasdaq Listing Rule 5250(c)(1), removing the immediate risk of delisting. Second, and perhaps more importantly, Celularity has completely retired its $32 million senior secured debt plus $9.6 million in unpaid interest - eliminating a substantial financial burden that was constraining operations.
The company has undergone significant restructuring, creating separate operating subsidiaries for each business unit, which typically enhances operational focus and accountability while potentially preparing certain divisions for strategic transactions. This follows an Asset Purchase Agreement and License Agreement with Celeniv Pte. Ltd., though specific financial terms weren't disclosed.
Reading between the lines, Celularity faced serious working capital challenges in early 2025. Despite growing wound care product sales in late 2024, the company experienced cash flow issues due to collection delays and "directional uncertainty around wound care product reimbursement policy." This suggests regulatory or insurance reimbursement complications temporarily disrupted their revenue cycle.
With debt eliminated and Nasdaq compliance restored, management believes they're now positioned to access traditional working capital facilities. This improved financial flexibility should support their three-pronged strategy: resuming wound care sales growth, advancing late-stage 510(k) pipeline products, and expanding into new markets for stem cell products, specifically mentioning Florida as a target.
- Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.
- Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1).
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Quarterly Reports on Form 10-Q can be accessed on the SEC's website at www.sec.gov and in the investor relations section of the Company’s website at https://celularity.com/sec-filings.
“I am pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025, as a result of which we have regained compliance with the Nasdaq Listing Rule 5250(c)(1). This is another important step for Celularity, as it comes on the heels of the recently announced retirement of all
“The Company dealt with a set of challenges during the first half of 2025, including a significant secured debt overhang. As announced previously, we retired all senior secured debt and the associated general security interest on Company assets is now gone. Also in the first half of 2025, some since-resolved directional uncertainty around wound care product reimbursement policy added to the normal lag between commercial advanced biomaterial product sales and cash collections. Coming as it did on the heels of substantial growth in the second half of 2024 of our wound care related commercial product sales and Accounts Receivable, this factor contributed to working capital pressures during the first half of 2025. Today, however, we believe the Company is well positioned to access traditional working capital facilities, which we intend to use to fuel renewed wound care related sales growth and advance our three late stage 510(k) pipeline products, along with capitalizing on new opportunities like stem cell product sales in Florida and elsewhere,” Dr. Hariri added.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.
Forward Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez Senior Vice President, Celularity Inc. Carlos.ramirez@celularity.com
FAQ
What did Celularity (CELU) announce about its Nasdaq compliance status?
How much debt did Celularity (CELU) retire in 2025?
What were the main challenges Celularity faced in H1 2025?
What are Celularity's growth plans following the debt retirement?
What strategic changes has Celularity implemented in 2025?
